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Hypothesis: Positron emission tomography can be useful in pre-
dicting response of esophageal cancer after preoperative chemo-
radiation therapy (CRT). We evaluated the use of integrated com-
puted tomography (CT)-PET among patients with esophageal cancer
being considered for resection after CRT.
Methods: Three reviewers blinded to clinical and pathologic staging
retrospectively reviewed the CT-PET scans of patients with esoph-
ageal cancer after preoperative CRT who underwent esophagec-
tomy. [18F]-fluoro-2-deoxy-D-glucose uptake for residual malig-
nancy was determined by visual analysis and semi-quantitatively
when standardized uptake value (SUV) was 4.
Results: Forty-two patients underwent esophageal resection. Using
visual analysis, CT-PET had a sensitivity of 47% and specificity of
58% in detecting residual malignancy. Using semi-quantitative anal-
ysis, 19 patients had a SUV 4 in the region of the primary
esophageal tumor and were interpreted as having residual malig-
nancy (sensitivity 43%, specificity 50%). Of these 19, six had
complete pathologic response to CRT. These false-positive results,
due to therapy-induced ulceration detected at endoscopy, limit the
use of CT-PET alone in detecting residual malignancy. Similarly,
sensitivity (25%) and specificity (73%) of endoscopy/biopsy in
detecting residual malignancy were poor. However, the accuracy of
CT-PET in detecting residual malignancy was improved when
combined with endoscopic findings. In the absence of ulceration at
endoscopy, 8 of 8 patients with SUV 4 after chemo-radiation had
residual malignancy at surgery.
Conclusions: CRT-induced ulceration results in false-positive re-
sults on CT-PET and precludes accurate detection of residual esoph-
ageal tumor. However, CT-PET in combination with endoscopy is
useful in identifying patients with a high risk of residual tumor
post-CRT.
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tion therapy.
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Esophageal cancer, an uncommon neoplasm with an esti-mated incidence of approximately 13,000 cases in the
United States in 2002, has been increasing in incidence over
the last few decades.1 There is no universally accepted
standard therapy; therefore, treatment is usually determined
by patient performance status, clinical disease stage, and
location of the primary cancer. Historically, treatment mo-
dalities have included surgery alone or chemotherapy with
radiation.2,3 More recently, multimodality therapy using pre-
operative chemotherapy and/or radiation followed by surgical
resection for suitable candidates has been used in an attempt
to improve survival.4–10
Computed tomography (CT) and endoscopy/endo-
scopic ultrasonography (EUS) are usually performed after
preoperative therapy to assess the primary tumor, detect
nodal and distant metastases, and determine tumor response.
However, a major limitation of these modalities is that they
are inaccurate in this determination.11–16 The use of positron
emission tomography (PET) with [18F]-fluoro-2-deoxy-D-
glucose (FDG) in the evaluation of patients with esophageal
cancer has been reported to be useful in predicting pathologic
response and the disease-free interval and overall survival of
patients after preoperative therapy.5,14,17–23 However, the
poor spatial resolution of PET compared with that of CT
often precludes accurate assessment of the primary tumor and
localization of nodal metastases, as well as detection of
pulmonary metastases. The recent use of integrated CT-PET
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imaging with co-registration of anatomical and functional
imaging data may improve the localization of regions of
increased FDG-uptake and accuracy of staging among pa-
tients with esophageal cancer.24,25 However, the role of FDG-
PET and integrated CT-PET imaging in patients with esoph-
ageal cancer after preoperative therapy has not been fully
elucidated. Therefore, in this article, we evaluate the role of
CT-PET imaging in determining response to preoperative
chemo-radiation therapy of the primary tumor and nodal
metastases in patients with esophageal cancer being consid-
ered for resection.
PATIENTS AND METHODS
We retrospectively evaluated 56 consecutive patients
with biopsy-proven primary esophageal cancer who were
treated with chemo-radiation therapy followed by esophagec-
tomy at our institution between February 2003 and July 2004.
To assess a more homogenous study group, patients were
excluded from the study group if CT-PET imaging was
performed more than 4 months after completion of chemo-
radiation therapy (n  7), esophageal resection was per-
formed more than 3 months after CT-PET imaging (n  1),
and detection of metastases by CT-PET imaging performed
after preoperative chemo-radiation therapy (n  4). Two
patients were excluded from the study group because of
detection of an unsuspected hepatic metastasis (n  1) and
non-resectable local disease because of invasion of the aorta
by esophageal malignancy (n  1) at the time of surgery
performed for planned esophagectomy. The M. D. Anderson
Cancer Center Institutional Review Board approved this
study.
Preoperative Staging and Treatment
All 42 patients included in this study were required to
have histologically diagnosed adenocarcinoma or squamous
cell cancer of the esophagus before undergoing multimodality
therapy. EUS, CT of the chest and abdomen, and PET
imaging (CT-PET [n  29], PET [n  11]) were performed
to determine pretreatment clinical stage. All patients were
assigned a tumor, node, metastasis classification and catego-
rized according to American Joint Commission on Cancer’s
2002 guidelines for pathologic and clinical staging as deter-
mined by using endoscopy/EUS, CT, and PET imaging.26
Patients whose tumors were considered to be resectable were
eligible to receive preoperative chemo-radiation therapy
(CRT). Criteria for preoperative CRT included: clinical stage
II-IVA, age 80 years old, consent to treatment, and ability
to tolerate esophagectomy as judged by multidisciplinary
assessment performed by a thoracic surgeon, medical oncol-
ogist, radiation oncologist, and diagnostic radiologist.
Treatment Plan
All patients who were candidates for preoperative CRT
were treated with chemotherapy followed by concurrent CRT
(n  21) or with concurrent CRT alone (n  21). Three
agents (fluorouracil, cisplatin, or a taxane) were used for
preoperative chemotherapy. For radiation therapy planning,
clinical target volume was defined as the gross tumor volume
plus a 5-cm margin superior to the highest extension and
inferior to the lowest extension of the cancer with a 2-cm
radial margin. The total dose of radiation therapy was 45 Gy
in 25 fractions or 50.4 Gy in 28 fractions prescribed to cover
at least 95% of the planning target volume.
After CRT, patients were clinically reassessed by en-
doscopy with or without EUS and whole-body integrated
CT-PET imaging. Esophagectomy was performed if a patient
could physiologically tolerate surgical resection and was
assessed as having stable disease or complete or partial
response of the primary tumor or nodal metastases to therapy
without interval development of systemic metastases. The
type of esophagectomy performed depended on the tumor’s
location and individual surgeon’s preference. Either a trans-
thoracic approach (Ivor-Lewis [two-field] or total [three-
field]) or a transhiatal approach to resection was used. Me-
diastinal and celiac lymph nodes were resected in all patients
who underwent surgery.
CT-PET Imaging Parameters
An integrated CT-PET scanner (Discovery ST-8; Gen-
eral Electric Medical Systems, Milwaukee, MN) was used.
PET images were acquired during shallow breathing in the
two-dimensional mode for 3 minutes per bed position 60 to
90 minutes after the intravenous administration of 555 to 740
MBq of FDG. PET images were reconstructed using standard
vendor-provided reconstruction algorithms with ordered sub-
set expectation maximization. Emission data were corrected
for scatter, random events, and dead-time losses with the
manufacturer’s software program, and images were recon-
structed both with and without attenuation correction. Non–
contrast-enhanced CT images were acquired in helical mode
(speed, 13.5 mm/rotation) from the base of the skull to the
mid thighs during suspended mid-expiration at 3.75-mm slice
thickness, 140 kVp, and 120 mA.
CT-PET Imaging Interpretation
Clinical staging of disease after CRT was performed
with CT-PET to assess for the presence of residual primary
esophageal cancer and or nodal metastases. Residual esoph-
ageal malignancy was considered present if FDG-uptake in
the region of the primary cancer was increased compared
with the adjacent esophagus; lymph nodes, regardless of size,
were interpreted as positive for metastasis if their FDG-
uptake was increased. To determine the sensitivity, specific-
ity, and accuracy of CT-PET in identifying residual esopha-
geal cancer and nodal metastasis after preoperative CRT and
before esophagectomy, three reviewers (two thoracic radiol-
ogists [J.J.E., R.F.M.] and one nuclear medicine physician
[H.A.M.]) blinded to the results of post-CRT endoscopy and
surgical pathology retrospectively interpreted the CT and
PET scans, and findings were recorded by consensus. Clinical
history, endoscopic reports, and all imaging studies per-
formed at the time of the initial diagnosis were available to
the readers.
The CT and PET images were reviewed on a Xeleris
workstation (General Electric Medical Systems). CT, PET,
and co-registered CT-PET images were available for review
in all standard planes along with maximal intensity whole-
body coronal projection images. PET scans were analyzed
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visually and semi-quantitatively. FDG uptake was considered
to be abnormal on visual analysis when uptake in the region
of the primary tumor was substantially greater than the
background activity of the adjacent esophagus on the atten-
uation-corrected images. Increased FDG-uptake in the pri-
mary tumor, loco-regional nodes, and distant metastatic dis-
ease was recorded. Additionally increased FDG-uptake in the
region of the primary tumor was graded as diffuse (cranio-
caudal extent 3 cm) or focal (craniocaudal extent 3 cm).
Diffuse and focal increased FDG-uptake was also visually
assessed as central, eccentric mural, or symmetric circumfer-
ential. A pixel region of interest was outlined within regions
of increased FDG-uptake and measured on each slice. Images
were not corrected for lean body mass, and maximal pixel
values were used. The highest recorded FDG-uptake was
semi-quantitatively analyzed, after correction for radioactive
decay, according to the following formula: maximal stan-
dardized uptake value (SUV)  mean region of interest
activity (mCi/mL)/injected dose (mCi)/body weight (g). To
reduce errors in the SUV measurements, standard calibrations
as recommended by the vendor were performed using 68-Ge
phantom cylinders, two- and three-dimensional normaliza-
tion, single attenuation daily uniformity/reference scans, and
monthly detector scans.
The CT scans were assessed for anatomic abnormality
of the esophagus, presence and location of enlarged thoracic
and abdominal lymph nodes and distant metastases. The
esophagus was evaluated for residual mass and wall thicken-
ing (radius 0.75 cm). Wall thickening was measured and
graded as symmetric or asymmetric and diffuse (craniocaudal
extent 3 cm) or focal (craniocaudal extent 3 cm).
Treatment Response Criteria
Resected specimens underwent routine histopathologic
examination and were also reviewed for tumor viability to
determine pathologic response. Residual esophageal cancer
was assessed semi-quantitatively based on the estimated per-
centage of viable cancer in relation to total cancer area,
including the amount of radiation-induced tissue injury in
mural histologic sections.27 The extent of viable cancer in the
esophagectomy specimen was assigned to one of three cate-
gories: no viable cancer (complete response), 1% to 50%
viable cancer (partial response), and 50% viable cancer (no
response) as modified from selected published grading sys-
tems for esophageal and gastric cancers.27–29
STATISTICAL ANALYSIS
The sensitivity, specificity, positive predictive value,
negative predictive value, and accuracy of CT-PET imaging
in assessing pathologic response in the primary tumor were
determined. The SUV of the esophagus after treatment was
compared with pathologic assessment of tumor response
using the one-way analysis of variance. Univariate analyses
were performed by 2 analysis. A two-tailed P value of 
0.05 was considered significant. Data analysis was performed
by our departmental biostatistician (A.M.C.) using SPSS
software (SPSS, Chicago, IL).
RESULTS
The final study group for assessment of the primary
tumor and nodal disease consisted of 42 patients (37 men, 5
women; mean age, 60 years [range, 23–75 years]). These
patients all underwent integrated CT-PET imaging within 3
months after chemo-radiation therapy (mean 33 days; range,
23-85 days) and esophageal resection within 3 months of
CT-PET imaging (mean 19 days; range, 3-86 days). Thirty-
five patients had adenocarcinoma, and six patients had squa-
mous cell cancer. In one patient, tumor morphology was
mixed. The primary tumor was located in the mid-esophagus
in three patients (7%) and in the lower esophagus or gastro-
esophageal junction in 39 patients (93%). Pretreatment clin-
ical stage was IIA/B (n 14), III (n 24), and IVA (n 4).
After chemo-radiation and esophageal resection, 11 patients
(26%) had pathologic stage 0 disease, five (12%) had stage I,
16 (38%) had stage IIA/B, nine (21%) had stage III, and one
(2%) had IVA disease. Pathologic response of the primary
esophageal tumor was complete (no viable cancer) in 12
patients (29%) and partial (1–50% viable cancer) in 25
patients (60%). Five patients (12%) had no response (50%
viable cancer) of the primary esophageal malignancy to
therapy.
CT-PET Response Evaluation
Visual Analysis
Nineteen patients had increased FDG-uptake in the
region of the known primary tumor greater than the FDG
activity in the adjacent irradiated esophagus by visual anal-
ysis and were interpreted as having residual malignancy.
FDG-uptake in the esophagus in the 19 patients in the region
of the primary esophageal malignancy was central (n  12)
and eccentric mural (n  7). Esophageal wall thickening in
the region of the primary malignancy (mean radius, 1.7 cm;
range, 0.9–2.8 cm) was symmetric and diffuse (mean cranio-
caudal extent 8.0 cm; range, 4–14 cm) in 15 patients and
symmetric and focal (mean craniocaudal extent 3 cm) in four
patients. Although these patients were interpreted as having
residual malignancy on CT-PET imaging, residual malig-
nancy was present in 14 patients at surgical resection (partial
response, n  9; no response, n  4). Six of 19 patients
(32%) had a complete pathologic response to therapy despite
an abnormal CT-PET interpretation.
Twenty-three patients had FDG-uptake in the region of
the known primary esophageal tumor the same or less than
FDG activity in the adjacent normal irradiated esophagus by
visual analysis and were interpreted to have no residual
malignancy. FDG-uptake in the region of the primary esoph-
ageal malignancy was central (n  8), eccentric mural (n 
7), and symmetric circumferential (n  8). Esophageal wall
thickening in the region of the primary malignancy (mean
radius, 1.4 cm; range, 0.8–2.1 cm) was symmetric and diffuse
(mean craniocaudal extent 7.6 cm; range, 4–16 cm) in 22
patients and symmetric and focal (craniocaudal extent 2 cm)
in one patient. Although these patients were interpreted as
having no residual malignancy on CT-PET imaging, com-
plete pathologic response to therapy was present in only
seven of 23 patients, primarily because CT-PET was unable
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to detect residual malignancy in partial pathologic respond-
ers. Histopathologic examination of resected specimens re-
vealed residual malignancy in 16 patients (partial response,
n  15; no response to therapy, n  1).
In the assessment of the primary esophageal tumor after
therapy, visual analysis of CT-PET had a sensitivity and
specificity of 47% and 58%, respectively, in evaluating for
residual esophageal tumor (PPV 74%, NPV 30%, accuracy
50%). Multiple assessments were also performed on the
post-CRT CT-PET scans, including esophageal wall thick-
ness and length of involvement on CT and SUV of primary
malignancy and distribution of FDG-uptake on PET. Univar-
iate logistic regression analysis of multiple imaging findings
demonstrated that there were no factors that predicted resid-
ual tumor (Table 1).
Semi-Quantitative Analysis
In the semi-quantitative assessment of the primary
esophageal tumor using a SUV of 4 as residual esophageal
tumor, CT-PET had a sensitivity and specificity of 43% and
50%, respectively (PPV 68%, NPV 26%, accuracy 45%), for
detecting residual malignancy. As SUV increased the sensi-
tivity of CT-PET decreased and the specificity increased
(Table 2). At a SUV designation of 7, the specificity
increased to 100%, but three of the 28 false-negative patients
had viable cancer 50%.
The poor sensitivity of CT-PET in differentiating those
patients who had residual cancer from those with a complete
response to therapy is, in large part, the result of the small
volume of disease below the detectability of FDG-PET im-
aging and the presence of therapy-induced FDG-avid esoph-
agitis and or ulceration. In this regard, 29 of the 42 patients
(69%) had esophagitis, and 25 (56%) had esophageal ulcer-
ation detected at endoscopy/EUS. FDG-uptake in the region
of the primary malignancy in the 25 patients with ulceration
ranged from 1.0 to 6.5 (mean, 3.7). The CT-PET appearance,
i.e., diffuse or focal wall thickening on CT and central,
eccentric mural, or symmetric circumferential FDG-uptake,
was not useful in differentiating those patients with residual
tumor from those with complete response and ulceration. Of
the 25 patients with therapy-induced ulceration, 11 had a
complete response to therapy. FDG-uptake in the region of
the primary malignancy in these 11 patients ranged from 1.0
to 6.5 (mean, 4.1); using SUV 4 as residual tumor, six
patients had a false-positive CT-PET. Among the 17 patients
with no ulceration at endoscopy, 13 had esophagitis. Eight of
the 17 patients without ulceration had increased uptake of
FDG at the tumor site with a SUV 4 (mean SUV, 8.4;
range, 4.0–30.0) and were considered to have residual tumor.
Three of these patients with 50% viable cancer and five
with 1% to 50% viable cancer (5–10% viable cancer in four
patients and 15% in one patient) were correctly identified.
Nine patients had a SUV 4 (mean SUV, 2.3; range, 1–3.9).
One patient had a complete response to therapy, seven had a
partial response, and one patient failed to respond to therapy.
Endoscopy/EUS Response Evaluation
All patients underwent endoscopy. Twenty-six patients
also had EUS, and biopsy was performed in 39. Compared
with resected esophageal specimens, 18 patients with partial
response (1–50% viable cancer) and three patients with no
response to therapy (50% viable cancer) had false-negative
biopsies. There were three false-positive biopsies, most likely
the result of progressive tumor death in the interval (mean, 23
days) between endoscopic biopsy and resection. Eight pa-
tients with complete response to therapy and seven patients
with persistent disease were correctly identified. The sensi-
tivity, specificity, PPV, NPV, and accuracy of endoscopic
biopsy in detecting malignancy were 25%, 73%, 70%, 28%,
and 38%, respectively.
TABLE 1. Univariate logistic regression analysis of imaging
findings for residual disease*
95% CI
Patients P value OR Lower Upper
Wall radius (cm) 0.932 0.938 0.218 4.039
SI length (cm) 0.956 0.995 0.823 1.203
SUV at tumor site 0.825 1.019 0.859 1.210
SUV post 5
No (Reference) 30 1.000
Yes 12 0.241 0.426 0.102 1.773
SUV post 4
No (Reference) 23 1.000
Yes 19 0.695 0.765 0.200 2.927
PET focal uptake
Single (Reference) 33 1.000
Multiple 9 0.722 0.750 0.154 3.654
Central, eccentric,
symmetric
0.771
Central (Reference) 20 1.000
Eccentric 14 0.502 0.600 0.135 2.662
Symmetric 8 1.000 1.000 0.151 6.643
Endoscopy ulceration
No (Reference) 17 1.000
Yes 25 0.022 12.571 1.437 110.009
OR, odds ratio; CI, confidence interval; SUV, standardized uptake value; PET,
positron emission tomography; SI, superior-inferior.
TABLE 2. Accuracy of Post-CRT PET in Detecting Residual
Disease1
PET Criteria Sensitivitya Specificityb Accuracyc
Abnormal primary tumor
(%) (visual, no SUV
criteria)
47 58 50
SUV criteria:
4 43 50 45
5 23 58 33
6 7 83 29
7 7 100 33
SUV, standardized uptake value; PET, positron emission tomography.
a Sensitivity  TP / (TP  FN).
b Specificity  TN / (TN  FP).
c Accuracy  (TP  TN) / (TP  FP  TN  FN).
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The finding of no ulceration on endoscopy after preop-
erative chemo-radiation was associated with a lack of re-
sponse to preoperative chemo-radiation and high chance of
residual cancer (Table 1). This factor was more predictive
than either the visual analysis or semi-quantitative SUV PET
analysis. The combination of increased SUV 4 and no
ulceration revealed a high-risk group of patient with malig-
nancy in all patients (n  8) (Table 3). Compared with SUV
4 and ulceration (5 of 11 patients with residual malignancy),
the combination of SUV 4 and no ulceration (8 of 8 patients
with residual malignancy) is better able to identify patients with
a high probability of residual malignancy (P  0.018).
TABLE 3. Accuracy of Post-CRT CT-PET and Endoscopy in Detecting Residual Disease Using a SUV Threshold of 4 and
Endoscopic Ulceration
Patient
Days from
treatment end to
CT-PET
Days from
CT-PET to
surgery
SUVmax
esophageal
cancer
CT-PET
interpretation of
residual cancer by
visual analysis
CT-PET
interpretation of
residual cancer by
SUV> 4
Endoscopy
ulceration
Endoscopy and CT-PET
SUV >4 prediction of
residual cancer
Response to
therapy
1 30 30 30 Yes Yes No Yes No
2 30 30 8.7 Yes Yes No Yes No
3 30 30 6.5 Yes Yes Yes No Complete
4 30 30 6.2 Yes Yes Yes No Complete
5 30 30 5.5 Yes Yes Yes No Complete
6 30 30 5.4 Yes Yes Yes No Complete
7 30 30 5.2 Yes Yes No Yes Incomplete
8 30 30 5.2 No Yes Yes No Complete
9 30 30 5.2 Yes Yes No Yes Incomplete
10 30 30 5.1 Yes Yes No Yes Incomplete
11 30 30 5 Yes Yes No Yes No
12 30 30 5 No Yes Yes No No
13 30 30 4.7 Yes Yes Yes No Incomplete
14 30 30 4.7 Yes Yes Yes No Incomplete
15 30 30 4.7 No Yes Yes No Incomplete
16 30 30 4.6 Yes Yes Yes No Incomplete
17 30 30 4.6 No Yes Yes No Complete
18 30 30 4 No Yes No Yes Incomplete
19 30 30 4 No Yes No Yes Incomplete
20 30 30 3.9 No No No No Complete
21 30 30 3.5 Yes No No No No
22 30 30 3.4 Yes No Yes No Incomplete
23 30 30 3.4 Yes No Yes No Incomplete
24 30 30 3.4 Yes No Yes No Complete
25 30 30 3.3 No No No No Incomplete
26 30 30 3 No No Yes No Incomplete
27 30 30 3 No No Yes No Incomplete
28 30 30 2.8 Yes No No No Incomplete
29 30 30 2.7 No No Yes No Complete
30 30 30 2.4 No No Yes No Complete
31 30 30 2.4 No No Yes No Incomplete
32 30 30 2.4 No No Yes No Incomplete
33 30 30 2.4 Yes No Yes No Incomplete
34 30 30 2 No No Yes No Incomplete
35 30 30 1.8 No No No No Incomplete
36 30 30 1.8 No No Yes No Complete
37 30 30 1.7 No No No No Incomplete
38 30 30 1.5 No No No No Incomplete
39 30 30 1.5 No No Yes No Incomplete
40 30 30 1.4 No No No No Incomplete
41 30 30 1 No No No No Incomplete
42 30 30 1 No No Yes No Complete
SUV, standardized uptake value; PET, positron emission tomography; CT, computed tomography.
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N Staging
There were no enlarged or FDG-avid nodes in the neck,
thorax, and abdomen of 39 patients (93%), and CT-PET scans
were interpreted as N0 (no regional metastases present).
Twenty-eight patients (67%) had N0 status confirmed patho-
logically after surgical resection. Eleven patients had micro-
scopic N1 disease in non-enlarged (1 cm) nodes (nodal
metastases in the regional lymph nodes) pathologically. Sen-
sitivity and specificity for residual nodal disease were 0% and
100%, respectively.
DISCUSSION
Multimodality treatment with chemotherapy, radiation,
and surgical resection is increasingly being used in patients
with locally advanced esophageal cancer.2,5,30 The appropri-
ate selection of patients who undergo preoperative CRT
followed by surgical resection is important, as this therapy is
associated with significant morbidity. In this regard, a signif-
icant improvement in survival has been shown among pa-
tients who respond to preoperative CRT with a complete
pathologic response.4,6,8,10,30,31 Thus, the clinical importance
of correctly differentiating these patients from those who fail
to respond to therapy may be important. Unfortunately, as-
sessment of TNM status by CT or endoscopy/endoscopic
biopsy after CRT often does not correlate with pathologic
response.11–13,16 In our study, endoscopy had limited clinical
utility in detecting esophageal malignancy after preoperative
CRT (sensitivity 25%, specificity 73%, accuracy 38%). In-
terestingly, three of the five patients with no response to
therapy (50% viable cancer) had false-negative biopsies.
CT-PET has been shown to have an important role in
the staging of esophageal cancer by identifying patients with
unsuspected metastatic disease, thus precluding surgical re-
section or definitive chemo-radiation.32,33 Recent studies have
also suggested that FDG-PET imaging may be useful in
assessing the response and prognosis of patients with esoph-
ageal cancer after induction therapy.14,17–23,34 The results of
these studies are varied: some authors report reliable assess-
ment of response to therapy,17–19,21,23 whereas others have
found that there is no correlation between decrease in SUV
and histopathology and that PET does not add to the evalu-
ation of loco-regional resectability.20,34 To determine whether
patients who fail to respond to CRT can be differentiated
from those with partial or complete response, we had previ-
ously evaluated the ability of FDG-PET imaging to predict
pathologic response.35,36 We reported that although PET is
unable to distinguish small-volume residual disease from a
complete pathologic response (0% viable cancer), PET is able
to identify patients who fail to respond to preoperative CRT
and have a poor long-term prognosis using a SUV threshold
of 4.35,36 However, the results of our current study show
that when a SUV 4 is used to identify patients who have
failed to respond (50% viable cancer) to preoperative CRT,
the accuracy of CT-PET is poor, with 15 of the 19 patients
having a false-positive result. This high false-positive rate is
most likely the result of the presence of metabolically active
leukocytes and macrophages associated with the inflamma-
tory esophagitis and ulceration that follow radiation thera-
py.37 In our current study, 25 patients (60%) had esophageal
ulceration detected at endoscopy; 11 of these patients had a
SUV 4. If a threshold SUV 4 is used to determine
therapeutic failure, 10 patients (91%) had a false-positive
CT-PET (six with complete response and four with partial
response [1–50% viable cancer]). In contrast, of the 17
patients without ulceration at endoscopy, eight had a SUV
4. Three of these patients were correctly identified as
non-responders (50% viable cancer) (Fig. 1). The five
FIGURE 1. A, Sagittal CT. B, PET.
C, Integrated CT-PET. Diffuse uptake
of [18F]-fluoro-2-deoxy-D-glucose in
the treated esophagus with SUV 8.7
in the region of the primary malig-
nancy. Endoscopy/EUS showed ab-
sence of esophagitis and ulceration.
CT-PET in combination with endos-
copy/EUS was interpreted as thera-
peutic failure. At resection, histopa-
thology confirmed 50% viable
tumor.
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patients interpreted as non-responders all had residual malig-
nancy (range, 5-15%).
A limitation of our study is the retrospective nature and
the variable periods of time between completion of chemo-
radiation and CT-PET. We attempted to correct for this
limitation by excluding patients who underwent surgery more
than 3 months after completion of chemo-radiation and strat-
ified for this limitation by grouping patients into those who
received their CT-PET more or less than 30 days after
completion of chemo-radiation. There was no clear correla-
tion shown between the timing of the CT-PET and the ability
to predict pathologic response, but these limitations highlight
the importance of confirming our findings with a prospective,
multi-institutional trial. Our study suggests that, used inde-
pendently, CT-PET was limited by the number of false-
positive results, and endoscopy/EUS and biopsy were limited
by the number of false-negative results. However, the accu-
racy of CT-PET in determining therapeutic response can be
improved when findings of ulceration on endoscopy/EUS are
incorporated into CT-PET interpretation. In this regard, if
patients with SUV 4 were found to have ulceration on
endoscopy, CT-PET was interpreted as response to therapy
(Table 3). In our study, 19 of the 42 patients (45%) had a
SUV 4 and would have been interpreted as having residual
tumor. Of these 19 patients, 11 had ulceration. Using ulcer-
ation at endoscopy as a discriminator, six of these patients
with a complete response to therapy and five patients with a
partial response would have been correctly identified. Three
of the four patients with no response to therapy had no
ulceration and would have been correctly identified. The
fourth patient had a discrete 3-cm ulcerated mass with 50%
viable tumor, which would have been interpreted as residual
malignancy on endoscopy. However, when combining endos-
copy and CT-PET, the presence of ulceration would have
been a confounding factor leading to misinterpretation as
therapeutic response.
In terms of CT-PET assessment of response of esoph-
ageal malignancy to preoperative CRT, esophagitis and ul-
ceration are important confounding factors (Fig. 2). Although
the form of preoperative therapy (radiation versus concurrent
chemo-radiation versus preoperative chemotherapy before
concurrent chemo-radiation) can affect ulceration rates, an-
other factor to consider is the timing of the post-CRT CT-
PET imaging. In our study, CT-PET was performed 4 to 6
weeks after CRT because of the need to perform a planned
esophagectomy during the prescribed time period. Clinical
studies have shown that the onset of inflammation/esophagitis
occurs approximately 2 weeks after the start of radiation.38
Weber and colleagues have reported low false-positive rates
for FDG-PET imaging when performed 2 weeks after the
initiation of preoperative chemotherapy for esophageal can-
cer (sensitivity 93%, specificity 95%).21 Furthermore, in a
study by Wieder et al., diffuse esophageal uptake of FDG
suggesting esophagitis was only observed in 15% of patients
(4 of 27 patients) when PET imaging was performed 14 days
after chemo-radiation therapy.15 Besides a lower incidence
than that in our study, the diffuse SUV uptake in their study
was low (mean SUV 2.6  0.3) and was unlikely to have
been interpreted as residual disease. Patients in the study by
Weber et al. were treated with chemotherapy only, and it is
uncertain whether the earlier imaging contributed to the lower
false-positive rate or whether this was the result of differ-
ences in therapeutic management.
In addition to showing that CT-PET interpreted to-
gether with findings on endoscopy/endoscopic biopsy de-
creases the number of false-positive results and can identify
patients who have residual disease after preoperative CRT,
our study concurs with prior studies that show that a negative
CT-PET is inaccurate in determining complete response to
therapy, i.e., CT-PET is unable to distinguish microscopic
residual disease from a complete pathologic response22,34,39
(Fig. 3). In our study, 23 of the 42 patients (55%) had a SUV
FIGURE 2. A, Coronal CT. B, PET.
C, Integrated CT-PET. Focal in-
creased [18F]-fluoro-2-deoxy-D-
glucose uptake in the region of the
esophageal malignancy SUV 6.5.
Endoscopy/EUS showed esophagitis
and ulceration. CT-PET in combina-
tion with endoscopy/EUS was inter-
preted as response to therapy. At
resection, histopathology revealed
complete response with 0% viable
tumor.
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4 (Table 3). These patients were interpreted as having no
residual malignancy on CT-PET imaging. However, only six
(26%) had a complete pathologic response. Although the
specificity of FDG-PET imaging after preoperative CRT is
poor, this can be improved by increasing the SUV cutoff, but
sensitivity is adversely affected (Table 2).36 The clinical
implication of this observation is that patients with an appar-
ently complete response after CRT can have residual disease
and that CT-PET imaging should not be used as the sole
criterion to determine whether patients should proceed to
esophagectomy. This recommendation is supported by the
study of Nakamura et al., who reported loco-regional recur-
rence in 42% of the patients who were treated with definitive
chemo-radiation and had a complete response according to
FDG-PET imaging.40
Another important observation of our study is that the
use of integrated CT-PET imaging with co-registration of
anatomical and functional imaging data was not accurate in
assessing response to therapy among patients with esophageal
cancer after CRT. In fact, multiple assessments performed on
the post-CRT CT-PET demonstrated that there were no fac-
tors that predicted residual tumor or failure of response to
therapy (Table 1). However, it is important to emphasize that
the use of CT-PET and endoscopy together allowed the
accurate identification of a subset of patients with residual
malignancy. In our study, eight of eight patients with a SUV
of 4 without ulceration as assessed by endoscopy had
residual malignancy at surgical resection. Currently, a treat-
ment option for patients with loco-regionally advanced
esophageal cancer is definitive chemo-radiation, followed by
observation and selective surgery for recurrent cancer. Our
study suggests that the group of esophageal cancer patients
with a SUV 4 and no ulceration on endoscopy after CRT
has a high risk of residual malignancy and should not be
observed. If these patients are physiologically fit and do not
have distant metastases, they should be considered for esoph-
agectomy. The retrospective nature of our study limits an
overall recommendation for a treatment algorithm. However,
clinicians who choose to treat their patients with definitive
chemo-radiation rather than chemo-radiation and surgery
may find these criteria useful in identifying a group of
patients with a high likelihood of having residual cancer for
whom continued observation alone may not be appropriate.
In summary, our study shows that post-CRT CT-PET
imaging interpretation for patients with esophageal cancer is
confounded by the presence of FDG-avid therapy-induced
ulceration. The high number of false-positive results pre-
cludes the use of CT-PET to definitively identify patients
with residual disease. However, the use of CT-PET in com-
bination with endoscopy is useful in identifying a subset of
patients with a high risk of residual malignancy.
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